The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Is The Market Size Of The Human Immunodeficiency Viruses (HIV) Clinical Trials Market Expected To Change Between 2026 And 2030?

Recent years have seen robust expansion in the human immunodeficiency viruses (hiv) clinical trials market. This market is projected to expand from $1.94 billion in 2025 to $2.11 billion by 2026, achieving a compound annual growth rate (CAGR) of 9.2%. Historically, this growth is a result of factors such as a significant global burden of HIV disease, broadening research into antiretroviral drugs, increased financial support for HIV studies from both public and private sources, the development of clinical research infrastructure, and regulatory frameworks supporting HIV drug innovation.

The human immunodeficiency viruses (hiv) clinical trials market is poised for significant expansion in the coming years. Projections indicate that the market will ascend to $2.97 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.9%. This anticipated growth throughout the forecast period stems from various factors, such as the intensified creation of both curative and preventive hiv therapies, an increasing embrace of adaptive trial frameworks, the broadening of hiv vaccine-focused trials, the expanding application of AI in clinical investigations, and a stronger emphasis on long-term safety and efficacy results. Furthermore, prominent developments expected during this period include the wider adoption of decentralized clinical trial paradigms, the increased utilization of digital platforms for patient recruitment, a sharpened focus on long-acting hiv therapies within trials, the broader integration of real-world evidence, and an augmented application of data analytics in the oversight of trials.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=28244&type=smp

What Drivers Are Expected To Influence The Human Immunodeficiency Viruses (HIV) Clinical Trials Market During The Forecast Period?

The rising frequency of human immunodeficiency virus (HIV) infections is projected to boost the expansion of the human immunodeficiency virus (HIV) clinical trials market in the future. Human immunodeficiency virus (HIV) infections describe a condition where the HIV virus compromises and weakens the immune system, making individuals more vulnerable to other infections and potentially progressing to AIDS. This increase in HIV infections primarily stems from insufficient public knowledge concerning transmission, which contributes to high-risk behaviors and belated testing, thereby facilitating the virus’s dissemination. Human immunodeficiency virus (HIV) clinical trials assist patients with HIV infections by evaluating novel drugs, vaccines, and therapeutic approaches aimed at enhancing prevention, more effectively managing the virus, and ultimately curbing disease advancement and spread. For instance, in August 2024, data from the Minority HIV/AIDS Fund (MHAF), a US-based government agency, indicated that an estimated 39.9 million individuals globally were living with HIV in 2023, comprising 38.6 million adults and 1.4 million children, compared to prior years. Consequently, the growing occurrence of human immunodeficiency virus (HIV) infections is propelling the expansion of the human immunodeficiency virus (HIV) clinical trials market.

How Is The Human Immunodeficiency Viruses (HIV) Clinical Trials Market Structured Across Different Segments?

The human immunodeficiency viruses (hiv) clinical trials market covered in this report is segmented –

1) By Phase: Phase I, Phase II, Phase III, Phase IV, Preclinical

2) By Drug Type: Antiretroviral Therapy (ART), Pre-Exposure Prophylaxis (PrEP), Post-Exposure Prophylaxis (PEP), Long-Acting Injectable Antiretrovirals, Experimental Drugs

3) By Study Design: Interventional Studies, Observational Studies, Expanded Access Studies

4) By Patient Population: Adults, Pediatric Patients, Seniors, Pregnant Women, High-Risk Populations

5) By End User: Pharmaceutical Companies, Research Institutes, Hospitals, Other End-Users

Subsegments:

1) By Phase I: First-In-Human Studies, Safety And Tolerability Studies

2) By Phase II: Dose-Finding Studies, Efficacy Studies

3) By Phase III: Pivotal Trials, Comparative Efficacy Studies

4) By Phase Iv: Post-Marketing Surveillance, Long-Term Safety Studies

5) By Preclinical: In Vitro Studies, Animal Studies

How Are Trends Impacting The Human Immunodeficiency Viruses (HIV) Clinical Trials Market?

Major companies within the human immunodeficiency virus (HIV) clinical trials market are concentrating on developing innovative solutions, such as HIV prevention injections, to enhance treatment efficacy and reduce transmission rates. An HIV prevention injection refers to a long-acting injectable medication administered periodically to prevent HIV infection in high-risk individuals by blocking the virus from establishing infection in the body. For instance, in August 2025, Gilead Sciences Inc., a US-based pharmaceutical company, received approval from the European Union for Yeytuo (lenacapavir) for HIV treatment. This is a twice-yearly injectable HIV prevention treatment that offers high efficacy, nearly 100% in clinical trials, significantly reducing the risk of sexually acquired HIV-1 infection. Its long-acting dosing improves adherence and convenience compared to daily oral PrEP, addressing a major gap in HIV prevention. Designed for adults and adolescents at increased risk, this aims to expand access and help reduce new HIV infections globally as part of comprehensive prevention strategies.

Which Major Players Dominate The Human Immunodeficiency Viruses (HIV) Clinical Trials Market?

Major companies operating in the human immunodeficiency viruses (hiv) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio

Read the full human immunodeficiency viruses (hiv) clinical trials market report here:

https://www.thebusinessresearchcompany.com/report/human-immunodeficiency-viruses-hiv-clinical-trials-global-market-report

Which Region Is Forecast To Lead The Human Immunodeficiency Viruses (HIV) Clinical Trials Market In Terms Of Market Size?

North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human immunodeficiency viruses (hiv) clinical trials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Human Immunodeficiency Viruses (HIV) Clinical Trials Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=28244&type=smp

Browse Through More Reports Similar to the Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market 2026, By The Business Research Company

Hiv Drug Global Market Report

https://www.thebusinessresearchcompany.com/report/hiv-drug-global-market-report

Antiviral Combination Therapy Global Market Report

https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report

Virtual Clinical Trials Global Market Report

https://www.thebusinessresearchcompany.com/report/virtual-clinical-trials-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model